Loading...

We've got a brand new version of Simply Wall St! Try it out

1933 Industries

CNSX:TGIF
Snowflake Description

Adequate balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
TGIF
CNSX
CA$95M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

1933 Industries Inc., a cannabis company, engages in the cultivation and production of medical marijuana in the United States and Canada. The last earnings update was 82 days ago. More info.


Add to Portfolio Compare Print
  • 1933 Industries has significant price volatility in the past 3 months.
TGIF Share Price and Events
7 Day Returns
-6.9%
CNSX:TGIF
-5.9%
CA Pharmaceuticals
1.3%
CA Market
1 Year Returns
-29.5%
CNSX:TGIF
-46.7%
CA Pharmaceuticals
-0.1%
CA Market
TGIF Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
1933 Industries (TGIF) -6.9% -4.3% -23% -29.5% 294.1% -
CA Pharmaceuticals -5.9% -3.4% -24.8% -46.7% 217.3% 286.4%
CA Market 1.3% 4.2% 1.6% -0.1% 8.4% 5.7%
1 Year Return vs Industry and Market
  • TGIF outperformed the Pharmaceuticals industry which returned -46.7% over the past year.
  • TGIF underperformed the Market in Canada which returned -0.1% over the past year.
Price Volatility
TGIF
Industry
5yr Volatility vs Market

Value

 Is 1933 Industries undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for 1933 Industries. This is due to cash flow or dividend data being unavailable. The share price is CA$0.335.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for 1933 Industries's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are 1933 Industries's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:TGIF PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-04-30) in CAD CA$-0.07
CNSX:TGIF Share Price ** CNSX (2019-09-20) in CAD CA$0.34
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 15.3x
Canada Market PE Ratio Median Figure of 539 Publicly-Listed Companies 14.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of 1933 Industries.

CNSX:TGIF PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:TGIF Share Price ÷ EPS (both in CAD)

= 0.34 ÷ -0.07

-4.9x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • 1933 Industries is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • 1933 Industries is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does 1933 Industries's expected growth come at a high price?
Raw Data
CNSX:TGIF PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.9x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
100.6%per year
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.56x
Canada Market PEG Ratio Median Figure of 245 Publicly-Listed Companies 1.02x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for 1933 Industries, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on 1933 Industries's assets?
Raw Data
CNSX:TGIF PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-04-30) in CAD CA$0.17
CNSX:TGIF Share Price * CNSX (2019-09-20) in CAD CA$0.34
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.36x
Canada Market PB Ratio Median Figure of 2,457 Publicly-Listed Companies 1.43x
CNSX:TGIF PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:TGIF Share Price ÷ Book Value per Share (both in CAD)

= 0.34 ÷ 0.17

1.98x

* Primary Listing of 1933 Industries.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • 1933 Industries is good value based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess 1933 Industries's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. 1933 Industries has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is 1933 Industries expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
100.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is 1933 Industries expected to grow at an attractive rate?
  • Unable to compare 1933 Industries's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare 1933 Industries's earnings growth to the Canada market average as it is expected to be loss making during the next 1-3 years.
  • 1933 Industries's revenue growth is expected to exceed the Canada market average.
Annual Growth Rates Comparison
Raw Data
CNSX:TGIF Future Growth Rates Data Sources
Data Point Source Value (per year)
CNSX:TGIF Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 100.6%
CNSX:TGIF Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 62.5%
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 97.7%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 56.5%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:TGIF Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:TGIF Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-07-31 34 -3 1
2019-09-22
2019-07-31 18 -15 1
CNSX:TGIF Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-04-30 17 -7 -16
2019-01-31 16 -4 -10
2018-10-31 15 -4 -8
2018-07-31 13 -4 -5
2018-04-30 10 -4 -4
2018-01-31 6 -4 -4
2017-10-31 3 -3 -3
2017-07-31 1 -2 -3
2017-04-30 -1 -3
2017-01-31 0 -3
2016-10-31 -1 -4
2016-07-31 -1 -4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • 1933 Industries is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • 1933 Industries's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:TGIF Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from 1933 Industries Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:TGIF Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-07-31 -0.01 -0.01 -0.01 1.00
2019-09-22
2019-07-31 -0.06 -0.06 -0.06 1.00
CNSX:TGIF Past Financials Data
Date (Data in CAD Millions) EPS *
2019-04-30 -0.07
2019-01-31 -0.05
2018-10-31 -0.03
2018-07-31 -0.03
2018-04-30 -0.02
2018-01-31 -0.03
2017-10-31 -0.06
2017-07-31 -0.06
2017-04-30 -0.10
2017-01-31 -0.13
2016-10-31 -0.19
2016-07-31 -0.21

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if 1933 Industries will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess 1933 Industries's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
1933 Industries has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has 1933 Industries performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare 1933 Industries's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • 1933 Industries does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare 1933 Industries's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare 1933 Industries's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
1933 Industries's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from 1933 Industries Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:TGIF Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-04-30 16.74 -16.43 15.35
2019-01-31 15.56 -10.29 13.09
2018-10-31 14.80 -7.93 11.58
2018-07-31 12.65 -5.49 8.96
2018-04-30 9.75 -3.77 7.00
2018-01-31 6.46 -3.72 5.89
2017-10-31 3.49 -3.10 4.03
2017-07-31 1.03 -2.61 2.58
2017-04-30 -2.62 1.29
2017-01-31 -2.92 1.00
2016-10-31 -3.67 1.70
2016-07-31 -3.67 1.70
2015-07-31 -0.16 0.16

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if 1933 Industries has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if 1933 Industries has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if 1933 Industries improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess 1933 Industries's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
1933 Industries has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is 1933 Industries's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up 1933 Industries's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • 1933 Industries is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • 1933 Industries's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of 1933 Industries's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from 1933 Industries Company Filings, last reported 4 months ago.

CNSX:TGIF Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-04-30 46.93 11.15 14.69
2019-01-31 39.13 11.86 8.81
2018-10-31 41.49 12.02 15.17
2018-07-31 36.98 2.00 5.06
2018-04-30 38.92 2.07 13.10
2018-01-31 31.61 2.66 15.75
2017-10-31 17.27 7.11 5.64
2017-07-31 16.01 1.78 0.60
2017-04-30 4.00 0.23 4.46
2017-01-31 -0.62 0.20 0.01
2016-10-31 -0.38 0.15 0.01
2016-07-31 -0.29 0.00 0.00
2015-07-31 0.33 0.00 0.00
  • 1933 Industries's level of debt (23.8%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if 1933 Industries's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • 1933 Industries has less than a year of cash runway based on current free cash flow.
  • 1933 Industries has sufficient cash runway for 2 years if free cash flow continues to grow at historical rates of 108.1% each year.
X
Financial health checks
We assess 1933 Industries's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. 1933 Industries has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is 1933 Industries's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from 1933 Industries dividends.
If you bought CA$2,000 of 1933 Industries shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate 1933 Industries's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate 1933 Industries's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:TGIF Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

CNSX:TGIF Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts
2020-07-31
2019-09-22
2019-07-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as 1933 Industries has not reported any payouts.
  • Unable to verify if 1933 Industries's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of 1933 Industries's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as 1933 Industries has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess 1933 Industries's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can 1933 Industries afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. 1933 Industries has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of 1933 Industries's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Chris Rebentisch
COMPENSATION CA$103,799
TENURE AS CEO 0.3 years
CEO Bio

Mr. Christopher Rebentisch, also known as Chris, has been Chief Executive Officer of 1933 Industries Inc., since May 29, 2019. Mr. Rebentisch has been Director of 1933 Industries Inc., since September 2018 and served as its U.S. Chief Operating Officer until May 29, 2019. After several years in entrepreneurial roles in the cosmetic manufacturing industry, combined with his belief in the natural healing properties of cannabis, Mr. Rebentisch founded Infused MFG in 2016. After personally developing and crafting a series of cannabis-based health and wellness products, Mr. Rebentisch launched the Canna Hemp™ brand in June, 2017. Mr. Rebentisch is a seasoned cultivator and advocate for the industry in the State of Nevada. Mr. Rebentisch began cultivating medical cannabis in 2011 as a state licensed caregiver until 2016, when he turned his focus to industrial hemp. Mr. Rebentisch’s depth of knowledge and expertise has made him an influencer in the field, where he is often invited to speak to academia and health care professionals about the viable applications of cannabis pharmacology as it applies to pain management and rehabilitation.

CEO Compensation
  • Insufficient data for Chris to compare compensation growth.
  • Chris's remuneration is lower than average for companies of similar size in Canada.
Management Team Tenure

Average tenure of the 1933 Industries management team in years:

0.5
Average Tenure
  • The average tenure for the 1933 Industries management team is less than 2 years, this suggests a new team.
Management Team

Chris Rebentisch

TITLE
CEO & Director
COMPENSATION
CA$104K
TENURE
0.3 yrs

Cameron Watt

TITLE
VP of Business Development & Director
COMPENSATION
CA$119K
TENURE
1.8 yrs

Ester Vigil

TITLE
President
TENURE
0.3 yrs

Steve Radusch

TITLE
Chief Financial Officer
TENURE
0.3 yrs

Alexia Helgason

TITLE
Director of Corporate Communications & Investor Relations
TENURE
0.7 yrs

Caleb Zobrist

TITLE
Executive VP & General Counsel
TENURE
1.7 yrs

Marion McGrath

TITLE
Company Secretary
AGE
58
Board of Directors Tenure

Average tenure of the 1933 Industries board of directors in years:

1.8
Average Tenure
  • The average tenure for the 1933 Industries board of directors is less than 3 years, this suggests a new board.
Board of Directors

Brayden Sutton

TITLE
Chairman
COMPENSATION
CA$178K
AGE
34
TENURE
0.3 yrs

Chris Rebentisch

TITLE
CEO & Director
COMPENSATION
CA$104K
TENURE
1 yrs

Cameron Watt

TITLE
VP of Business Development & Director
COMPENSATION
CA$119K
TENURE
1.6 yrs

Rick Skeith

TITLE
Independent Director
AGE
66
TENURE
3.8 yrs

Drew Milburn

TITLE
Member of Advisory Board
TENURE
2.2 yrs

Anthony Torres

TITLE
Member of Advisory Board
TENURE
2.1 yrs

Brian Farrell

TITLE
Independent Director
TENURE
3.4 yrs

Terry Taouss

TITLE
Independent Director
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
10. Jun 19 Buy Theodore Taoussanopoulos Individual 10. Jun 19 10. Jun 19 20,000 CA$0.47 CA$9,500
02. Apr 19 Buy Brayden Sutton Individual 02. Apr 19 02. Apr 19 100,000 CA$0.51 CA$51,000
X
Management checks
We assess 1933 Industries's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. 1933 Industries has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Is 1933 Industries (CNSX:TGIF) Weighed On By Its Debt Load?

The image below, which you can click on for greater detail, shows that at April 2019 1933 Industries had debt of CA$11.2m, up from CA$2.07m in one year. … CNSX:TGIF Historical Debt, August 14th 2019 How Strong Is 1933 Industries's Balance Sheet? … This short term liquidity is a sign that 1933 Industries could probably pay off its debt with ease, as its balance sheet is far from stretched.

Simply Wall St -

Did 1933 Industries Inc. (CNSX:TGIF) Insiders Buy Up More Shares?

In the last twelve months 1933 Industries insiders were buying shares, but not selling. … 1933 Industries Insiders Bought Stock Recently We saw some 1933 Industries insider buying shares in the last three months. … We would certainly prefer see higher levels of insider ownership but analysis of the insider transactions suggests that 1933 Industries insiders are expecting a bright future.

Simply Wall St -

Company Info

Description

1933 Industries Inc., a cannabis company, engages in the cultivation and production of medical marijuana in the United States and Canada. The company produces, packages, and markets industrial hemp-based and cannabidiol (CBD) infused products, such as flowers and concentrates, as well as canna hemp, pet, and X products. It also offers CBD extraction services; and cannabis advisory services in security, intelligence, and due diligence. The company was formerly known as Friday Night Inc. and changed its name to 1933 Industries Inc. in September 2018. 1933 Industries Inc. was incorporated in 2008 and is headquartered in Chilliwack, Canada.

Details
Name: 1933 Industries Inc.
TGIF
Exchange: CNSX
Founded: 2008
CA$95,451,792
284,930,725
Website: http://www.1933Industries.com
Address: 1933 Industries Inc.
105, 45655 Tamihi Way,
Chilliwack,
British Columbia, V2R 2M3,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX TGIF New Common Shares Canadian National Stock Exchange CA CAD 01. Dec 2015
OTCPK TGIF.F New Common Shares Pink Sheets LLC US USD 01. Dec 2015
DB 1QF New Common Shares Deutsche Boerse AG DE EUR 01. Dec 2015
Number of employees
Current staff
Staff numbers
70
1933 Industries employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/22 00:44
End of day share price update: 2019/09/20 00:00
Last estimates confirmation: 2019/09/16
Last earnings filing: 2019/07/02
Last earnings reported: 2019/04/30
Last annual earnings reported: 2018/07/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.